Prognostic significance of the estrogen-regulated protein, cathepsin D, in breast cancer. An immunohistochemical study
β Scribed by J. A. Henry; Anne L. McCarthy; B. Angus; B. R. Westley; Felicity E. B. May; S. Nicholson; J. Cairns; A. L. Harris; C. H. W. Horne
- Publisher
- John Wiley and Sons
- Year
- 1990
- Tongue
- English
- Weight
- 648 KB
- Volume
- 65
- Category
- Article
- ISSN
- 0008-543X
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
## Background: Between january 11, 1991 and january 8, 1992, 104 patients with previously untreated, invasive, primitive breast carcinoma were admitted to the authors' hospital. ## Methods: For each patient, flow cytometry dna analyses on frozen samples and on immunohistochemical staining were pe
Background. Cathepsin D is a lysosomal protease overexpressed and abnormally secreted in most breast cancer cells. Several retrospective clinical studies have shown that cathepsin D is an independent prognostic factor in breast cancer that is associated with a higher risk of recurrence and a shorter
BACKGROUND. This study evaluated the prognostic significance of immunohistochemical staining for cathepsin D, epidermal growth factor receptor (EGFR). and c-erbB-2 in patients with early cervical squamous cell carcinoma. ## METHODS. This retrospective analysis comprised 132 patients, all subjecte
Background. The response to endocrine therapy is not entirely predictable from the estrogen receptor (ER) and progesterone receptor (PgR) status of primary breast tumors. The authors previously proposed a new prognostic factor, ER.R, which was based on both ER protein and mRNA levels. A previous ana
In many cancer cell lines, including breast, prostate, lung, brain, head and neck, retina, and the gastrointestinal tract, opioids decrease cell proliferation in a dose-dependent and reversible manner. Opioid and/or other neuropeptide receptors mediate this decrease. We report that only the steroid-